Dateline City: SAN FRANCISCO SAN FRANCISCO–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the first results from the Tryton Side Branch Stent Pivotal IDE trial were presented during a Late Breaking Clinical Trial session at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The Tryton Pivotal IDE trial is an international, …
Global Bifurcation Leader Tryton Medical Announces Events at TCT 2013
Dateline City: SAN FRANCISCO First Results from the Tryton Side Branch Stent Pivotal IDE Trial Will Be Presented Wednesday, October 30 in a Late Breaking Clinical Trial Session SAN FRANCISCO–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced activities highlighting the latest data and experience with the Tryton Side Branch Stent at the …
Tryton Medical Introduces Physician Education Program
Dateline City: DURHAM, N.C. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced it has introduced a physician education program, starting with the Tryton Bifurcation Case of the Month. The Tryton Bifurcation Case of the Month series highlights physician review and analysis of a patient case that employed dedicated bifurcation stenting. The …
Tryton Medical Announces CE Mark and European Launch of Next-Generation Tryton Side Branch SHORT Stent
Dateline City: DURHAM, N.C. New Stent Will Be Featured at EuroPCR 2013 Exhibit Booth #M27 May 21-24 in Paris DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced that the company received the CE Mark for the Tryton Side Branch SHORT Stent, a novel coronary stent system that broadens the treatment options …
Tryton Medical Announces Completion of Patient Enrollment in Landmark Pivotal Study of Side Branch Stent
Dateline City: DURHAM, N.C. Study Is the First and Largest Randomized Multi-Center Bifurcation Trial Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the completion of enrollment in the TRYTON Pivotal IDE trial evaluating the Tryton Side Branch Stent.™ The landmark Tryton pivotal study is an international randomized trial that compares a Tryton …
Tryton Announces Events at EuroPCR 2012
Dateline City: DURHAM, N.C. Two-Hour Session Will Feature Two Live Cases; Pooled Analysis of Bifurcation Stent System Will Examine Evidence from Eight Clinical Studies DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced activities highlighting the latest experience with the TRYTON Side Branch Stent at EuroPCR, the official congress of the …
4000th Patient Treated With Innovative Tryton Side Branch Stent
Dateline City: DURHAM, N.C. Positive Real-World Data From Tryton Stent System Presented at Joint Interventional Meeting in Rome DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that more than 4000 patients have been treated with the company’s Tryton™ Side Branch Stent in Europe, Russia and the Middle East. New data …
Tryton Announces DRG Reimbursement Code For Side Branch Stent in Germany
Dateline City: DURHAM, N.C. New Code Signals Growing Market Acceptance for Side Branch Stents DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced that the German Institute for Medical Documentation and Information (DIMDI, Cologne) has revised the procedure code for the treatment of coronary bifurcations lesions, distinguishing dedicated side branch stent systems …
IVUS Cohort Recruitment Complete in Landmark Tryton IDE Study
Dateline City: DURHAM, N.C. More Than 175 Patients Enrolled in Multi-National Pivotal Trial DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced completion of patient enrollment in the intravascular ultrasound (IVUS) cohort of the randomized, controlled Tryton IDE Study evaluating the TRYTON Side Branch Stent for the treatment of bifurcation disease. …
Tryton’s Innovative Solution Highlighted at Annual European Bifurcation Club Meeting
Dateline City: DURHAM, N.C. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical’s TRYTON Side Branch Stent™ System was discussed as an important new therapeutic option for patients with bifurcation disease last week at the annual European Bifurcation Club (EBC) meeting in Lisbon, Portugal, where approximately 150 international interventional cardiologists gathered to share best practices for challenging bifurcation cases. Patrick W. Serruys, M.D., Ph.D., of …